Haemonetics is trading 6.18% up at $111.12 after investors continued reacting to its non-exclusive supply agreement with CSL Plasma.
- The agreement allows CSL to deploy Haemonetics’ NexSys PCS devices with Persona PLUS technology and purchase related disposables at U.S. plasma centers.
- There are no minimum purchase commitments, but investors viewed CSL’s return as platform validation and a potential plasma-volume catalyst.
- The move follows Haemonetics’ 15.93% gain on August 18, while broader futures were mixed rather than strongly supportive.